{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+High+Risk+Myelodysplastic+Syndrome&page=2",
    "query": {
      "condition": "Recurrent High Risk Myelodysplastic Syndrome",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+High+Risk+Myelodysplastic+Syndrome&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-06-10T18:12:16.432Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00334074",
      "title": "Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Myelodysplastic Syndromes",
        "Chronic Myelogenous Leukemia"
      ],
      "interventions": [
        {
          "name": "Clofarabine and Cytarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 30,
      "start_date": "2005-08",
      "completion_date": "2008-02",
      "has_results": true,
      "last_update_posted_date": "2013-07-17",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00334074"
    },
    {
      "nct_id": "NCT00064311",
      "title": "Ravuconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Stem Cell Transplantation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Chronic Myeloproliferative Disorders",
        "Gestational Trophoblastic Tumor",
        "Infection",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Myelodysplastic/Myeloproliferative Neoplasms",
        "Neuroblastoma",
        "Ovarian Cancer",
        "Testicular Germ Cell Tumor"
      ],
      "interventions": [
        {
          "name": "ravuconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institutes of Health Clinical Center (CC)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2003-06",
      "completion_date": "2004-09",
      "has_results": false,
      "last_update_posted_date": "2012-03-08",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00064311"
    },
    {
      "nct_id": "NCT03600155",
      "title": "Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell Transplantation Recipient",
        "Myelodysplastic Syndrome",
        "Recurrent Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2018-10-11",
      "completion_date": "2024-12-02",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03600155"
    },
    {
      "nct_id": "NCT01692197",
      "title": "E7070, Idarubicin and Cytarabine in Relapsed AML and High-Risk Myelodysplastic Syndromes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "E7070",
          "type": "DRUG"
        },
        {
          "name": "Idarubicin",
          "type": "DRUG"
        },
        {
          "name": "Cytarabine",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2013-02-01",
      "completion_date": "2017-06-07",
      "has_results": true,
      "last_update_posted_date": "2018-07-03",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01692197"
    },
    {
      "nct_id": "NCT04749355",
      "title": "Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "AML, Adult",
        "MDS",
        "Relapse/Recurrence",
        "Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "BST-236",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioSight Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2021-11-14",
      "completion_date": "2024-03-14",
      "has_results": false,
      "last_update_posted_date": "2023-03-09",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 4,
      "location_summary": "Shreveport, Louisiana • Houston, Texas • Charlottesville, Virginia + 1 more",
      "locations": [
        {
          "city": "Shreveport",
          "state": "Louisiana"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Charlottesville",
          "state": "Virginia"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04749355"
    },
    {
      "nct_id": "NCT05961839",
      "title": "Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "High-Risk and Very High-Risk Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "SGR-2921",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Schrödinger, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2023-09-27",
      "completion_date": "2025-09-09",
      "has_results": false,
      "last_update_posted_date": "2025-09-22",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 12,
      "location_summary": "Denver, Colorado • Fairway, Kansas • Buffalo, New York + 9 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05961839"
    },
    {
      "nct_id": "NCT01168219",
      "title": "Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Adult Acute Megakaryoblastic Leukemia",
        "Adult Acute Monoblastic Leukemia",
        "Adult Acute Monocytic Leukemia",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With Maturation",
        "Adult Acute Myeloid Leukemia With Minimal Differentiation",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11",
        "Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1",
        "Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-MLL",
        "Adult Acute Myeloid Leukemia Without Maturation",
        "Adult Acute Myelomonocytic Leukemia",
        "Adult Erythroleukemia",
        "Adult Pure Erythroid Leukemia",
        "Alkylating Agent-Related Acute Myeloid Leukemia",
        "de Novo Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome",
        "Myelodysplastic Syndrome With Excess Blasts",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Anti-Thymocyte Globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine Phosphate",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "74 Years",
        "sex": "ALL",
        "summary": "18 Years to 74 Years"
      },
      "enrollment_count": 68,
      "start_date": "2010-07-15",
      "completion_date": "2020-02-01",
      "has_results": true,
      "last_update_posted_date": "2022-08-04",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 17,
      "location_summary": "Lewes, Delaware • Newark, Delaware • Orlando, Florida + 12 more",
      "locations": [
        {
          "city": "Lewes",
          "state": "Delaware"
        },
        {
          "city": "Newark",
          "state": "Delaware"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01168219"
    },
    {
      "nct_id": "NCT00119366",
      "title": "Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Total Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Childhood Myelodysplastic Syndromes",
        "Chronic Myelomonocytic Leukemia",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Refractory Anemia With Excess Blasts",
        "Refractory Anemia With Excess Blasts in Transformation",
        "Refractory Anemia With Ringed Sideroblasts",
        "Refractory Cytopenia With Multilineage Dysplasia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "iodine I 131 monoclonal antibody BC8",
          "type": "RADIATION"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "16 Years to 50 Years"
      },
      "enrollment_count": 18,
      "start_date": "2003-05",
      "completion_date": "2019-05-08",
      "has_results": true,
      "last_update_posted_date": "2022-12-12",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00119366"
    },
    {
      "nct_id": "NCT00004036",
      "title": "Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Myeloproliferative Disorders",
        "Drug/Agent Toxicity by Tissue/Organ",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes",
        "Precancerous Condition",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "amifostine trihydrate",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "The Cleveland Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "1997-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-12-19",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004036"
    },
    {
      "nct_id": "NCT01760655",
      "title": "Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Myeloid Leukemia With FLT3/ITD Mutation",
        "Acute Myeloid Leukemia With Gene Mutations",
        "Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM",
        "Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214",
        "Aplastic Anemia",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Chronic Myelomonocytic Leukemia",
        "Follicular Lymphoma",
        "Hodgkin Lymphoma",
        "Myelodysplastic Syndrome",
        "Myelofibrosis",
        "Myeloid Leukemia",
        "Non-Hodgkin Lymphoma",
        "Plasma Cell Myeloma",
        "Polycythemia Vera",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Refractory Acute Myeloid Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Therapy-Related Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Total-Body Irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Therapeutic Allogeneic Lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Hematopoietic Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Peripheral Blood Stem Cell Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "BIOLOGICAL",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 62,
      "start_date": "2012-12-24",
      "completion_date": "2022-12-05",
      "has_results": true,
      "last_update_posted_date": "2025-10-30",
      "last_synced_at": "2026-06-10T18:12:16.432Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01760655"
    }
  ]
}